ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2649

Prevalence of Cancer in Systemic Lupus Erythematosus

Ana Lucia Barbaglia1, Maria de la Paz Leon1, Luciana Gonzalez Lucero1, Raul Sueldo2, Maria Constanza Bertolaccini1, Francisco Javier Hüttmann1, Susana Mazza1, Yessika Soria Curi1, Maria Lilia Leguizamon1, Mirta Santana2, Liliana Galindo1, Ramiro Maldonado1, Veronica Bellomio1, Maria Victoria Collado3, Romina Rojas Tessel4, Aciar Mariana4 and Eleonora Lucero1, 1Hospital Angel C. Padilla, Tucuman, Argentina, 2Hospital Angel C. Padilla, Tucumán, Argentina, 3Lanari Institute, Buenos Aires, Argentina, 4Hospital del Milagro, Salta, Argentina

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: SLE and cancer

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster III: Treatment

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

– Background/Purpose:  Cancer is one of the main causes of morbidity and mortality worldwide. The overall risk of cancer in SLE is higher than in the general population (SIR 1.14). Objectives: To determine the incidence and prevalence of cancer in patients with SLE. To identify prevalent types of cancer and associated risk factors. To estimate mortality of patients with SLE due to neoplastic etiology.

– Methods: A cohort study was conducted, all medical charts of patients diagnosed with SLE (ACR 1982/97 classification criteria) by different Rheumatology Services from January 2000 to June 2016 were reviewed. We studied sociodemographic variables and those related to SLE and to cancer. Statistical analysis: Descriptive, Prevalence, Incidence, Chi²-exact test, T Test and Mann Whitney, ANOVA, Multiple Linear Regression, Kaplan-Meier curves.

– Results: We included 303 SLE patients, 88.4% women.  Twenty-two cancers were diagnosed in 18 patients, determining a prevalence of 5.9% [IC95% 3.3-8.6] and an annual incidence rate of 5.2 / 1000 inhabitants, both rates being higher compared to the general population (p= 0.0001, p = 0.02 respectively), and a risk of cancer of 2.4. The mean age at diagnosis of cancer was 46 ± 12.9 years, 94.4% were women and 16.6% (3/18) had a family history of cancer. Five types of cancers were observed: 8 cervical, 3 breast, 3 ovarian, 3 thyroid, 1 non-Hodgkin’s lymphoma. All patients received treatment (14 surgeries, 1 chemotherapy and 3 combined), 15 remitted and 2 developed metastases. Three patients had 2 cancers and 1 patient had 3. There was no association between the presence of cancer and smoking, alcoholism, obesity or immunosuppressive treatment. Patients with cancer had more comorbidities such as arterial hypertension (55.5% vs 44.5%, p = 0.031) and diabetes (22.2% vs 3.9%, p = 0.009) compared with those who did not have cancer. In the regression analysis, greater cumulative damage, older age at diagnosis of SLE, longer disease duration and HPV infection were significantly associated with cancer.  The mean survival time in patients with SLE who had cancer was 10.8 years. Thirty   six patients died, 33 due to other causes and 3 due to cancer. The cancer mortality rate per year was 3.9%.

– Conclusion: The prevalence of cancer in patients with SLE was 5.9%, with an annual incidence of 5.2 / 1000 inhabitants.  The most frequent types of cancer were: cervix, breast, ovarian, thyroid and lymphoma. The risk factors that were associated with cancer were HPV infection, higher SLICC/SDI, older age at diagnosis of SLE and longer time of evolution of SLE.  The death rate due to cancer was 3.9%.


Disclosure: A. L. Barbaglia, None; M. D. L. P. Leon, None; L. Gonzalez Lucero, None; R. Sueldo, None; M. C. Bertolaccini, None; F. J. Hüttmann, None; S. Mazza, None; Y. Soria Curi, None; M. L. Leguizamon, None; M. Santana, None; L. Galindo, None; R. Maldonado, None; V. Bellomio, None; M. V. Collado, None; R. Rojas Tessel, None; A. Mariana, None; E. Lucero, None.

To cite this abstract in AMA style:

Barbaglia AL, Leon MDLP, Gonzalez Lucero L, Sueldo R, Bertolaccini MC, Hüttmann FJ, Mazza S, Soria Curi Y, Leguizamon ML, Santana M, Galindo L, Maldonado R, Bellomio V, Collado MV, Rojas Tessel R, Mariana A, Lucero E. Prevalence of Cancer in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/prevalence-of-cancer-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-cancer-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology